Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1/2 3Phase 3 2Phase NA 1Phase 2/3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 7Carcinoma, Hepatocellular 4Rectal Neoplasms 2Stomach Neoplasms 1Peripheral Nervous System Diseases 1Neoplasm Metastasis 1Liver Neoplasms 1Colonic Neoplasms 1Biliary Tract Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 11Docetaxel 8Fluorouracil 6Capecitabine 6Leucovorin 5Drug Therapy 5apatinib 4Trastuzumab 4S 1 (combination) 4Tegafur 3Paclitaxel 3Nivolumab 3Irinotecan 3Cisplatin 3sintilimab 2disitamab vedotin 2Surgical Procedures, Operative 2Standard of Care 2Ramucirumab 2Hyperthermic Intraperitoneal Chemotherapy 2Epirubicin 2vinflunine 1toripalimab 1titanium silicide 1tislelizumab 1taxane 1polysaccharide-K 1pertuzumab 1margetuximab 1gimeracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Stomach Neoplasms × Folfox protocol × Clear all
NCT07221149 2026-05-14

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Bristol-Myers Squibb

Phase 2/3 Recruiting
690 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡